摘要
目的以阿米替林为对照,评价盐酸文拉法辛胶囊预防偏头痛的疗效及安全性。方法79例偏头痛患者随机分成盐酸文拉法辛组(n=40)和阿米替林组(n=39),盐酸文拉法辛组服用盐酸文拉法辛胶囊75 mg/d,阿米替林组服用阿米替林75mg/d,疗程均为3月。治疗前、治疗1个月、2个月和3个月后分别评价患者的头痛发作次数、严重程度和头痛持续时间,以及治疗后1个月、2个月和3个月的不良反应发生情况。结果经盐酸文拉法辛和阿米替林治疗1月、2月及3月后,患者的头痛发作次数、严重程度及持续时间均显著改善,差异有统计学意义;同时治疗2个月疗效好于1个月,治疗3个月疗效好于2个月;两组患者治疗前后各时点头痛发作次数、严重程度、持续时间比较无统计学差异。但阿米替林不良反应发生率显著高于盐酸文拉法辛,分别是77.8%和21%,差异有统计学意义。结论盐酸文拉法辛预防偏头痛疗效确切,安全性好。
Objective To evaluate the efficacy and safety of venlafaxine（VLF） in the prophylaxis of migraine com- pared with amitriptyline（AMT）. Methods Seventy nine patients with migraine were randomly assigned to VLF 75mg group（ n = 40） and AMT group（ n = 39）. The frequency of headache attacks, the severity and duration of attacks were monitored before treatment and every one month after treatment for 3 months. Adverse events were also evaluated during these visits. Results Significant differences were observed between before treatment and every one month after treat- ment in the number of headache attacks, the severity and duration of attacks （P 〈 0.05, or P 〈0.01 ） in both groups. Significant differences were also observed between 2nd month and 1st month（ P 〈0.05, or P 〈0.01 ） , 3th month and 2nd month（P 〈0.05, or P 〈0.01 ） after treatment in the 3 parameters in both groups. There were no significant differ- ences between two groups in the 3 parameters at each visit. The prevalence of adverse events was significantly higher in AMT group（77.8% ） than that in VLF group（21% ） （ P 〈 0.01 ）. Conclusion Venlafaxine is effective and safe for prophylaxis of migraine.
出处
《精神医学杂志》
2009年第5期341-343,共3页
Journal of Psychiatry
